

# 15-ICML HIGHLIGHTS

## 15<sup>th</sup> International Conference on Malignant Lymphoma

KSAU-HS Convention Center – Hall A, Ministry of National Guard – Health Affairs

Friday, 04 October 2019



Organized by:

SAUDI LYMPHOMA GROUP  
المجموعة السعودية لأورام الخد الخبيثة

In collaboration with  
**SS BMT**  
الجمعية السعودية لزراعة خلايا الدم الجذعية  
SAUDI SOCIETY OF BLOOD & MARROW TRANSPLANTATION



### 15-ICML HIGHLIGHTS PROGRAM

Friday, 04 October 2019

Time	Mins.	Topic	Speaker
7:30 – 8:00	30'	Registration	
8:00 – 8:05	5'	Opening and Program Overview	Mubarak Al Mansour
8:05 – 8:10	5'	Welcome Remarks - ICML	Davide Rossi
SESSION ONE: Turki Alwasaidi / Saeed Shieban			
8:10 – 8:35	25'	Liquid Biopsy	Davide Rossi
8:35 – 9:00	25'	Aggressive Lymphoma	Andrew Davies
9:00 – 9:15	15'	Abst: Robust: First report of Phase 3 Randomized study of Lenalidomide/R-CHOP (R2-CHOP) VS Placebo/R2-CHOP in previously untreated ABC-type Diffuse Large B-Cell Lymphoma	Mohammed Darweesh
9:15 – 9:30	15'	Abst: Smart Start: Rituximab, Lenalidomide, and Ibrutinib alone prior to combination with Chemotherapy for patients with newly diagnosed Diffuse Large B-Cell Lymphoma	John Apostolidis
9:30 – 9:45	15'	Abst: Polarix: A Phase 3 Study of Polatuzumab Vedotin (POLA) plus R-CHP versus R-CHOP in patients with untreated DLBCL	Mohammad Bakkar
9:45 – 10:00	15'	Discussion	
10:00 – 10:15	15'	Coffee Break	
SESSION TWO: Ahmed Alsagheir			
10:15 – 10:40	25'	Update in Hodgkin's Lymphoma – Part 1	Andreas Engert
10:40 – 10:55	15'	Abst: Sintilimab for Relapsed/Refractory (R/R) Extranodal NK/T Cell Lymphoma (ENKTL) : A multicenter, Single-Arm, Phase 2 Trial (ORIENT-4)	Reyad Dada
10:55 – 11:10	15'	Abst: Nivolumab combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety from the Phase 2 Checkmate 436 Study	Amer Aleem
11:10 – 11:25	15'	Discussion	
11:25 – 12:35	70'	JUMA'AH PRAYER & LUNCH BREAK	
12:35 – 1:00	25'	SATELLITE SYMPOSIA – AML Updates	Musa Al Zahrani
SESSION THREE: Riad Elfakih			
1:00 – 1:40	40'	Follicular Lymphoma	Andrew Davies
1:40 – 1:55	15'	Abst: Obinutuzumab plus DHAP followed by Autologous Stem Cell Transplantation (ASCT) plus Obinutuzumab maintenance provides a high MRD response rate in untreated MCL patients, results of LYMA-101 Trial, A LYSA group study	Ihab Elhemaidi
1:55 – 2:10	15'	Abst: First-line therapy of T-Cell Lymphoma: Allogeneic or Autologous Transplantation for Consolidation - Final Results of the AATT study	Khadega Ahmed
2:10 – 2:25	15'	Discussion	
2:25 – 2:40	15'	Coffee Break	
SESSION FOUR: Khalid Alsaleh			
2:40 – 3:05	25'	Biomarkers-guided management of Chronic Lymphocytic Leukemia	Davide Rossi
3:05 – 3:30	25'	Update in Hodgkin's Lymphoma – Part 2	Andreas Engert
3:30 – 3:45	15'	Abst: High Efficacy of Venetoclax plus Obinutuzumab in patients with Complex Karyotype (CKT) and Chronic Lymphocytic Leukemia (CLL): A Prospective Analysis from the CLL14 Trial	Musa Al Zahrani
3:45 – 4:00	15'	Abst: Outcome of Primary Mediastinal Large B-Cell Lymphoma in the Rituximab Era: Impact of a PET-guided approach	Mohsen Al Zahrani
4:00 --		DISCUSSION & CLOSING REMARKS	

### EVENING SATELLITE SYMPOSIA & GALA DINNER

Friday, 04 October 2019, 7:00 P.M. – 8:30 P.M.

Sheraton Hotel Riyadh

7:00 – 7:15	Registration
7:15 – 8:00	R/R CLL management & treatment goals evolution (Speaker: Clemens Wendther) – Sponsored by ABBVIE
8:00 --	Dinner